Abstract:As promising therapeutic targets for various types of cancers, Aurora kinases A and B share high sequence and structural similarity, posing a challenge for designing subtype-selective small-molecule inhibitors. Since Aurora kinase A functions as both an oncogene and a haploinsufficient tumor suppressor, selectively inhibiting Aurora kinase B with highly specific inhibitors offers a less toxic anti-cancer strategy. However, the molecular mechanism governing ligand selectivity for Aurora kinase B over A remains unclear. In this study, we used Barasertib, an experimentally validated ligand with 1000-fold selectivity for Aurora kinase B over A, as a template molecule to investigate the selectivity mechanism through molecular dynamics simulations and binding free energy analyses. Our studied showed that in the ATP-binding pocket, the hinge residue Arg159 (−2.21 kcal/mol), exclusive to Aurora kinase B, significantly contributed to Barasertib binding, whereas no such binding occurred with the corresponding residue Leu215 (−0.10 kcal/mol) in Aurora kinase A. In the hydrophobic back pocket, the sum of binding free energies for key residues Lys106, Glu125, and Asp218 in Aurora kinase B (−4.02 kcal/mol) was substantially lower than that (7.89 kcal/mol) for the corresponding residues Lys162, Glu181, and Asp274 in Aurora kinase A. This finding suggests that binding interactions at the hydrophobic back pocket play a crucial role in Barasertib's selectivity for Aurora kinase B over A. Interestingly, in contrast to the complexes without partner proteins, the binding of partner proteins in both Aurora kinase A and B models induced the aC helix and the beta sheets in the N-lobe to move inward towards the ATP-binding pocket, resulting in a smaller hydrophobic back pocket and unfavorable Barasertib binding. In summary, our results demonstrate how differential ligand behavior arises from a complex interplay of subtle but relevant structural differences upon binding to distinct kinase subtypes. The insights into the structural determinants of subtype selectivity will facilitate the development of highly selective and potent Aurora kinase B inhibitors as drug candidates for cancer therapy.

Molecular Docking and Molecular Dynamics Simulation Studies to Identify Potent AURKA Inhibitors: Assessing the Performance of Density Functional Theory, MM-GBSA and Mass Action Kinetics Calculations

Identification of Potent Inhibitors against Aurora Kinase A Using Molecular Docking and Molecular Dynamics Simulation Studies

Three-Dimensional Quantitative Structure-Activity Relationships and Molecular Dynamic Simulations Studies to Discover Aurora Kinase-B Inhibitors

Identification of Aurora A kinase allosteric inhibitors: A comprehensive virtual screening through fingerprint-based similarity search, molecular docking, machine learning and molecular dynamics simulation

Structural insight into Aurora A kinase based on molecular dynamics simulations

Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes

The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations

Computer-assisted Discovery and Evaluation of Potential Ribosomal Protein S6 Kinase Beta 2 Inhibitors

Design and Synthesis of (E)-3-benzylideneindolin-2-one Derivatives As Potential Allosteric Inhibitors of Aurora A Kinase

Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold

Breaking the 'undruggable' barrier: Revealing molecular mechanisms in Aurora Kinase A/Myc protein interplay targeting cancers

Discovery of N -benzylbenzamide-based allosteric inhibitors of Aurora kinase A

Selective targeting of Aurora kinase B over A: Uncovering the structural basis for inhibitor specificity through molecular dynamics simulations

2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6

Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): Amalgamation of both spectroscopic and computational approach

MD and EPR studies of the structure and dynamics of the MTSL spin-labelled activation loop of the Aurora-A kinase

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor